title: Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.
authors: Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, SCCT Mezzanine MS 35, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
authors: Swati
authors: S
authors: Sikaria
authors: Josefine
authors: J
authors: Heim-Hall
authors: Elizabeth H
authors: EH
authors: Diaz
authors: Ronald
authors: R
authors: Williams
authors: Kamelesh
authors: K
authors: Sankhala
authors: Brenda
authors: B
authors: Laabs
authors: Monica
authors: M
authors: Mita
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068338:Everolimus; D005870:Giant Cell Tumors / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D017746:Joint Capsule / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017451:Receptors, Somatomedin / Q000037:antagonists & inhibitors / Q000276:immunology; D012785:Shoulder Joint / Q000473:pathology*; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012983:Soft Tissue Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D013710:Tendons / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017451:Receptors, Somatomedin; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; C573312:robatumumab; D020123:Sirolimus